PMID- 16030187
OWN - NLM
STAT- MEDLINE
DCOM- 20051215
LR  - 20240316
IS  - 0006-4971 (Print)
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Linking)
VI  - 106
IP  - 10
DP  - 2005 Nov 15
TI  - Relationship of patient survival and chromosome anomalies detected in metaphase 
      and/or interphase cells at diagnosis of myeloma.
PG  - 3553-8
AB  - The clinical efficacy of evaluating genetic anomalies in metaphase cells versus 
      interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, 
      survival for 154 patients with newly diagnosed untreated MM was compared with 
      results from analysis of metaphase and interphase cells. Metaphases were studied 
      by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in 
      situ hybridization [FISH]), whereas inter-phase nuclei were evaluated only by 
      FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), 
      t(11;14)(q13;q32), t(14;16)(q32;q23), del(17) (p13.1), and chromosome 13 
      anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 
      (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, 
      including each patient with abnormal metaphases. FISH was a necessary adjunct to 
      cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival 
      was especially poor for patients with greater than 50% abnormal interphase 
      nuclei, although this result was more likely due to level of plasma cells than 
      specific chromosome anomalies. For metaphase data, patients with t(4;14), 
      t(14;16), del(17) (p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) 
      had poor survival. A different outcome was observed for interphase data as 
      patients with t(4;14) or t(14;16) had poor survival, whereas patients with 
      chromosome 13 anomalies had intermediate survival: interphase FISH did not 
      substitute for metaphase analysis.
FAU - Dewald, Gordon W
AU  - Dewald GW
AD  - Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA. gdewald@mayo.edu
FAU - Therneau, Terry
AU  - Therneau T
FAU - Larson, Dirk
AU  - Larson D
FAU - Lee, You Kyoung
AU  - Lee YK
FAU - Fink, Stephanie
AU  - Fink S
FAU - Smoley, Stephanie
AU  - Smoley S
FAU - Paternoster, Sarah
AU  - Paternoster S
FAU - Adeyinka, Adewale
AU  - Adeyinka A
FAU - Ketterling, Rhett
AU  - Ketterling R
FAU - Van Dyke, Daniel L
AU  - Van Dyke DL
FAU - Fonseca, Rafael
AU  - Fonseca R
FAU - Kyle, Robert
AU  - Kyle R
LA  - eng
GR  - P01 CA62242/CA/NCI NIH HHS/United States
GR  - P50 CA100707-01/CA/NCI NIH HHS/United States
GR  - R01 CA83724-01/CA/NCI NIH HHS/United States
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20050719
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - *Chromosomes, Human/genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/methods
MH  - *Interphase/genetics
MH  - Male
MH  - *Metaphase/genetics
MH  - Middle Aged
MH  - Multiple Myeloma/diagnosis/genetics/*mortality
MH  - Predictive Value of Tests
PMC - PMC1895058
EDAT- 2005/07/21 09:00
MHDA- 2005/12/16 09:00
PMCR- 2006/11/15
CRDT- 2005/07/21 09:00
PHST- 2005/07/21 09:00 [pubmed]
PHST- 2005/12/16 09:00 [medline]
PHST- 2005/07/21 09:00 [entrez]
PHST- 2006/11/15 00:00 [pmc-release]
AID - S0006-4971(20)68501-9 [pii]
AID - 01063553 [pii]
AID - 10.1182/blood-2005-05-1981 [doi]
PST - ppublish
SO  - Blood. 2005 Nov 15;106(10):3553-8. doi: 10.1182/blood-2005-05-1981. Epub 2005 Jul 
      19.